65,000 people in the United States have Neurotrophic Keratitis
Neurotrophic keratitis (NK) is a rare degenerative corneal disorder caused by impaired corneal innervation
NK is characterized by reduced corneal sensitivity, spontaneous corneal epithelium breakdown, and impaired corneal healing.  Many conditions that damage the corneal nerves including herpetic keratitis, diabetes and surgical procedures can cause patients to develop NK.  The disease can lead to a variety of complications, including poor wound healing of the cornea, scarring of the cornea, and loss of vision. 

NRO-1 recovers ocular surface function through regenerating corneal nerves and directly accelerating corneal wound healing

NRO-1 has the optimal product profile for the treatment of NK

There is currently one approved therapy for NK, Oxervate (cenegermin), which has a number of drawbacks, including high discontinuation rates in clinical trials due to safety and tolerability issues, as well as a lack of convenience (refrigerated product delivered via pipette six times per day).

NRO-1 has the potential to become the ideal therapy for physicians and patients by addressing the key deficiencies of Oxervate.  


The key differentiators of NRO-1 are:

  • NRO-1 is a topically delivered small molecule that can be stored at room temperature

  • Targets GDNF as opposed to NGF (which is associated with increased pain/irritation)

  • Safety and tolerability are similar to vehicle in a Phase 1 SAD/MAD clinical study

We plan to initiate a Phase 2 study with NRO-1 in patients with neurotrophic keratitis in 2020